P134: Engaging the nurse navigator to increase genetic testing rate for metastatic prostate cancer patients

Since the addition of metastatic prostate cancer to the NCCN guidelines as an indication for germline genetic testing, our institution has struggled to incorporate genetic testing into the care plan. Baseline data for calendar year 2021 found a genetic testing rate of 28% (20 of 71 total cases) within this population.